• BridgeBio Pharma average return on tangible equity for 2024 was 40.29, a 9.87% increase from 2023.
• BridgeBio Pharma average return on tangible equity for 2023 was 44.7, a 17.39% decline from 2022.
• BridgeBio Pharma average return on tangible equity for 2022 was 54.11, a 210.14% decline from 2021.

Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.